Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
DEL MAR, Calif., May 1, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to a prespecified subgroup analysis in children with fast-progressing myopia from the Phase 3 STAR trial of SYD-101 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting taking place May 3-7, 2026 in Denver, Colorado. Presentation Details […]